Cargando…

Microbial Therapeutics in Neurocognitive and Psychiatric Disorders

Microbial therapeutics, which include gut biotics and fecal transplantation, are interventions designed to improve the gut microbiome. Gut biotics can be considered as the administration of direct microbial populations. The delivery of this can be done through live microbial flora, certain food like...

Descripción completa

Detalles Bibliográficos
Autores principales: Alagiakrishnan, Kannayiram, Halverson, Tyler
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510649/
https://www.ncbi.nlm.nih.gov/pubmed/34691318
http://dx.doi.org/10.14740/jocmr4575
_version_ 1784582619722153984
author Alagiakrishnan, Kannayiram
Halverson, Tyler
author_facet Alagiakrishnan, Kannayiram
Halverson, Tyler
author_sort Alagiakrishnan, Kannayiram
collection PubMed
description Microbial therapeutics, which include gut biotics and fecal transplantation, are interventions designed to improve the gut microbiome. Gut biotics can be considered as the administration of direct microbial populations. The delivery of this can be done through live microbial flora, certain food like fiber, microbial products (metabolites and elements) obtained through the fermentation of food products, or as genetically engineered substances, that may have therapeutic benefit on different health disorders. Dietary intervention and pharmacological supplements with gut biotics aim at correcting disruption of the gut microbiota by repopulating with beneficial microorganism leading to decrease in gut permeability, inflammation, and alteration in metabolic activities, through a variety of mechanisms of action. Our understanding of the pharmacokinetics of microbial therapeutics has improved with in vitro models, sampling techniques in the gut, and tools for the reliable identification of gut biotics. Evidence from human studies points out that prebiotics, probiotics and synbiotics have the potential for treating and preventing mental health disorders, whereas with paraprobiotics, proteobiotics and postbiotics, the research is limited at this point. Some animal studies point out that gut biotics can be used with conventional treatments for a synergistic effect on mental health disorders. If future research shows that there is a possibility of synergistic effect of psychotropic medications with gut biotics, then a gut biotic or nutritional prescription can be given along with psychotropics. Even though the overall safety of gut biotics seems to be good, caution is needed to watch for any known and unknown side effects as well as the need for risk benefit analysis with certain vulnerable populations. Future research is needed before wide spread use of natural and genetically engineered gut biotics. Regulatory framework for gut biotics needs to be optimized. Holistic understanding of gut dysbiosis, along with life style factors, by health care providers is necessary for the better management of these conditions. In conclusion, microbial therapeutics are a new psychotherapeutic approach which offer some hope in certain conditions like dementia and depression. Future of microbial therapeutics will be driven by well-done randomized controlled trials and longitudinal research, as well as by replication studies in human subjects.
format Online
Article
Text
id pubmed-8510649
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-85106492021-10-22 Microbial Therapeutics in Neurocognitive and Psychiatric Disorders Alagiakrishnan, Kannayiram Halverson, Tyler J Clin Med Res Review Microbial therapeutics, which include gut biotics and fecal transplantation, are interventions designed to improve the gut microbiome. Gut biotics can be considered as the administration of direct microbial populations. The delivery of this can be done through live microbial flora, certain food like fiber, microbial products (metabolites and elements) obtained through the fermentation of food products, or as genetically engineered substances, that may have therapeutic benefit on different health disorders. Dietary intervention and pharmacological supplements with gut biotics aim at correcting disruption of the gut microbiota by repopulating with beneficial microorganism leading to decrease in gut permeability, inflammation, and alteration in metabolic activities, through a variety of mechanisms of action. Our understanding of the pharmacokinetics of microbial therapeutics has improved with in vitro models, sampling techniques in the gut, and tools for the reliable identification of gut biotics. Evidence from human studies points out that prebiotics, probiotics and synbiotics have the potential for treating and preventing mental health disorders, whereas with paraprobiotics, proteobiotics and postbiotics, the research is limited at this point. Some animal studies point out that gut biotics can be used with conventional treatments for a synergistic effect on mental health disorders. If future research shows that there is a possibility of synergistic effect of psychotropic medications with gut biotics, then a gut biotic or nutritional prescription can be given along with psychotropics. Even though the overall safety of gut biotics seems to be good, caution is needed to watch for any known and unknown side effects as well as the need for risk benefit analysis with certain vulnerable populations. Future research is needed before wide spread use of natural and genetically engineered gut biotics. Regulatory framework for gut biotics needs to be optimized. Holistic understanding of gut dysbiosis, along with life style factors, by health care providers is necessary for the better management of these conditions. In conclusion, microbial therapeutics are a new psychotherapeutic approach which offer some hope in certain conditions like dementia and depression. Future of microbial therapeutics will be driven by well-done randomized controlled trials and longitudinal research, as well as by replication studies in human subjects. Elmer Press 2021-09 2021-09-30 /pmc/articles/PMC8510649/ /pubmed/34691318 http://dx.doi.org/10.14740/jocmr4575 Text en Copyright 2021, Alagiakrishnan et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Alagiakrishnan, Kannayiram
Halverson, Tyler
Microbial Therapeutics in Neurocognitive and Psychiatric Disorders
title Microbial Therapeutics in Neurocognitive and Psychiatric Disorders
title_full Microbial Therapeutics in Neurocognitive and Psychiatric Disorders
title_fullStr Microbial Therapeutics in Neurocognitive and Psychiatric Disorders
title_full_unstemmed Microbial Therapeutics in Neurocognitive and Psychiatric Disorders
title_short Microbial Therapeutics in Neurocognitive and Psychiatric Disorders
title_sort microbial therapeutics in neurocognitive and psychiatric disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510649/
https://www.ncbi.nlm.nih.gov/pubmed/34691318
http://dx.doi.org/10.14740/jocmr4575
work_keys_str_mv AT alagiakrishnankannayiram microbialtherapeuticsinneurocognitiveandpsychiatricdisorders
AT halversontyler microbialtherapeuticsinneurocognitiveandpsychiatricdisorders